Ming Fang

Managing Director

Rob Faulkner

Managing Director

Jeremy Green

Founder and Portfolio Manager

Michael Lee

Managing Director / Co-Founder

188 past transactions

Bambusa Therapeutics

Series A in 2025
Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.

Abcuro

Series C in 2025
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Clear Labs

Series D in 2025
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Saluda Medical

Venture Round in 2025
Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.

Rapt

Post in 2024
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Scancell

Post in 2024
Scancell is focused on developing innovative therapeutic vaccines aimed at treating cancer and infectious diseases, leveraging its proprietary technology platforms, ImmunoBody and Moditope. The company is advancing its lead cancer vaccine, SCIB1, which targets melanoma and is currently in Phase 1/2 clinical trials. Preliminary data from these trials indicated that SCIB1 may elicit an immune response potentially linked to clinical benefits for patients with malignant melanoma. Scancell's ImmunoBody platform is designed to generate strong T cell responses that specifically target and eliminate tumor cells, while the Moditope technology addresses immune suppression caused by tumors, enabling activated T cells to effectively attack otherwise concealed cancer cells.

Neurogene

Post in 2024
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.

Candid Therapeutics

Series A in 2024
Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

GRO Biosciences

Series B in 2024
GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Lycia Therapeutics

Series C in 2024
Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Attovia Therapeutics

Series B in 2024
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Hansa Biopharma

Post in 2024
Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative and life-altering therapies that address critical unmet medical needs in areas such as transplantation, autoimmune diseases, gene therapy, and oncology. Hansa Biopharma employs a proprietary antibody-cleaving enzyme technology platform to target disease-causing antibodies. Its lead product candidate, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is being explored for potential applications in other organ transplants and acute autoimmune conditions. The company operates primarily in Sweden, other European countries, and the United States, generating most of its revenue from product sales.

Ventyx Biosciences

Post in 2024
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Impulse Dynamics

Venture Round in 2024
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Cogent Biosciences

Post in 2024
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

Sensorion

Post in 2024
Sensorion is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. The company's lead product, SENS-401, is currently in phase II clinical trials aimed at treating sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-111, which is in phase II trials for acute unilateral vestibulopathy, and SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company also collaborates with Cochlear Limited to explore combination therapies for patients with cochlear implants. Founded in 2009, Sensorion is dedicated to conducting research and development to discover drugs that can restore and treat hearing loss, positioning itself as a key player in the field of otology.
Silence Therapeutics is a biotechnology company based in London, focused on the discovery, development, and delivery of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company specializes in designing short interfering RNA (siRNA) molecules that activate the RNA interference (RNAi) pathway to selectively degrade target messenger RNAs. Its product pipeline includes SLN124, aimed at treating iron overload disorders, SLN360, which targets cardiovascular diseases associated with elevated lipoprotein levels, and SLN500 for complement-mediated diseases. Silence Therapeutics has established strategic collaborations with AstraZeneca to develop small interfering RNA therapeutics for a range of diseases, and with Genomics England Limited. The company was previously known as SR Pharma before rebranding in 2007.

EmployerDirect Healthcare

Secondary Market in 2023
“Surgery Plus has been a valuable benefit in helping us to both reduce our costs and improve the overall perception of our benefit programs to our employees. We have achieved significant savings off of carrier negotiated discounts and the employees have had very positive medical experiences. I highly recommend the program!”

AC Immune

Post in 2023
AC Immune is a clinical-stage biopharmaceutical company based in Switzerland, dedicated to developing therapeutic and diagnostic products for neurodegenerative diseases linked to protein misfolding. Utilizing its proprietary technology platforms, the company creates antibodies, small molecules, and vaccines aimed at preventing and modifying these diseases. Its lead candidate, crenezumab, is a monoclonal antibody currently undergoing Phase II clinical trials for Alzheimer’s disease. Other notable candidates include ACI-24, an anti-Abeta vaccine in Phase II trials for Alzheimer’s and Down syndrome, ACI-35, an anti-Tau vaccine that has completed Phase Ib trials, and RG6100, an anti-Tau antibody in Phase II studies for Alzheimer’s patients. Additionally, AC Immune is exploring Tau Morphomer aggregation inhibitor small molecules and has diagnostics targeting various protein aggregates. The company has established collaborations with several prominent organizations, including Genentech and Biogen, and has a research partnership with the University of Pennsylvania focusing on TDP-43 in neurodegenerative diseases. Founded in 2003, AC Immune is headquartered in Lausanne, Switzerland.

Scancell

Post in 2023
Scancell is focused on developing innovative therapeutic vaccines aimed at treating cancer and infectious diseases, leveraging its proprietary technology platforms, ImmunoBody and Moditope. The company is advancing its lead cancer vaccine, SCIB1, which targets melanoma and is currently in Phase 1/2 clinical trials. Preliminary data from these trials indicated that SCIB1 may elicit an immune response potentially linked to clinical benefits for patients with malignant melanoma. Scancell's ImmunoBody platform is designed to generate strong T cell responses that specifically target and eliminate tumor cells, while the Moditope technology addresses immune suppression caused by tumors, enabling activated T cells to effectively attack otherwise concealed cancer cells.

AgomAb Therapeutics

Series C in 2023
AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Star Therapeutics

Series C in 2023
Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Abcuro

Series B in 2023
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

ADARx Pharmaceuticals

Series C in 2023
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Sensorion

Post in 2023
Sensorion is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. The company's lead product, SENS-401, is currently in phase II clinical trials aimed at treating sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-111, which is in phase II trials for acute unilateral vestibulopathy, and SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company also collaborates with Cochlear Limited to explore combination therapies for patients with cochlear implants. Founded in 2009, Sensorion is dedicated to conducting research and development to discover drugs that can restore and treat hearing loss, positioning itself as a key player in the field of otology.

Immunome

Post in 2023
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.

ElevateBio

Series D in 2023
ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, focused on the development of cell and gene-based therapies for treating cancer and viral infections. Founded in 2017 by Vikas Sinha, Mitchell Finer, and David Hallal, ElevateBio operates a portfolio of companies dedicated to creating life-changing medicines. The company collaborates with leading scientists and innovators to build this portfolio and has established a centralized facility that streamlines the transition from research and development to the commercialization of these therapies. This integrated approach enhances efficiency and accelerates the availability of medical products aimed at addressing severe diseases.

Krystal Biotech

Post in 2023
Krystal Biotech is a biopharmaceutical company using gene therapy to develop best in class treatments that provide significant clinical benefit for patients suffering from rare debilitating disorders.

Boundless Bio

Series C in 2023
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

Orbital Therapeutics

Series A in 2023
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. To produce an extended portfolio of medications, the company is developing an innovative platform at the confluence of RNA technology, delivery techniques, data analytics, and automation.

Augmedix

Post in 2023
Augmedix, Inc. is a healthcare technology company based in San Francisco, California, with additional offices in Menlo Park and Dhaka, Bangladesh. Founded in 2012, Augmedix specializes in remote medical documentation and live clinical support through its cloud-based platform. The application transforms natural clinician-patient conversations into organized medical notes in real time, allowing healthcare providers to focus more on patient care and reducing the administrative burden associated with electronic health record documentation. By partnering with hospitals and health systems, Augmedix enhances clinical efficiency and decision-making, ultimately improving operational and financial outcomes. The platform is designed for use by both large healthcare organizations and individual practitioners, charging service fees for access to its remote documentation and clinical support services.

Saluda Medical

Venture Round in 2023
Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.

Escient Pharmaceuticals

Series C in 2022
Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Ventyx Biosciences

Post in 2022
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Kymera Therapeutics

Post in 2022
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

AlloVir

Post in 2022
AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.

Annexon Biosciences

Post in 2022
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Scholar Rock

Post in 2022
Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Rapt

Post in 2022
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Neuron23

Series C in 2022
Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Saluda Medical

Private Equity Round in 2022
Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.

Star Therapeutics

Venture Round in 2022
Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Electra Therapeutics

Series B in 2022
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment.
The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

Home Biosciences

Seed Round in 2021
Home Biosciences is a European venture builder dedicated to biotech.

GRO Biosciences

Series A in 2021
GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Sphere Fluidics

Venture Round in 2021
Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

Science 37

Post in 2021
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.

Gritstone bio

Post in 2021
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Mammoth Biosciences

Series D in 2021
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Lycia Therapeutics

Series B in 2021
Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Attralus

Series B in 2021
Attralus, Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from systemic amyloidosis. The company develops innovative peptide-based agents aimed at diagnosing and treating various forms and stages of this complex condition. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic applications; and AT-03, an Fc-fusion protein designed for therapeutic use. Attralus focuses on addressing the common pathology found in all systemic amyloidosis diseases, striving to create effective treatments for subtypes that currently lack available options. Founded in 2010 and headquartered in South San Francisco, California, Attralus was previously known as Aurora Bio, Inc. before rebranding in August 2020.

Zentera Therapeutics

Series B in 2021
Zentera Therapeutics is a biopharmaceutical company.

Thriveworks

Venture Round in 2021
Thriveworks is a provider of mental health services that focuses on counseling and psychiatric support for individuals facing various life challenges. The company offers a range of services, including therapy for depression and anxiety, marriage counseling, life coaching, and support for relationship issues, low self-esteem, and trauma. Thriveworks emphasizes the importance of personalized care, ensuring that clients receive tailored plans that address their unique mental health needs. Through its diverse offerings, Thriveworks aims to promote overall well-being and assist individuals in navigating their mental health concerns.

Prime Medicine

Series B in 2021
Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Strand Therapeutics

Series A in 2021
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.

Mnemo Therapeutics

Series A in 2021
Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.

RayzeBio

Series C in 2021
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Quantum SI

Post in 2021
Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Clear Labs

Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

HydraFacial

Post in 2021
HydraFacial is an FDA registered manufacturer of advanced aesthetic technologies and products, delivering high return on investment (ROI) opportunities. Its premier system HydraFacial® serum-based hydradermabrasion system, ranked one level above IPL for skin rejuvenation. The HydraFacial uses the patented HydroPeel® tips to resurface the skin while simultaneously infusing skin enhancing serums, including antioxidants, Hyaluronic Acid, peptide complex, and acid peels.

Ceribell

Series C in 2021
Ceribell, Inc. is a medical technology company that designs and manufactures devices for electroencephalography (EEG) data acquisition and interpretation, aimed at improving the diagnosis and management of neurological conditions. Its flagship product, the Ceribell EEG System, includes a flexible EEG Headband that accommodates various hair types and head sizes, alongside a portable EEG Recorder that ensures clinical-quality data and on-device display. The system is designed to be set up by any healthcare provider within six minutes, making EEG testing more accessible and efficient. Notably, it features a unique function that converts brainwaves into sound, allowing for quicker detection of seizures without the need for specialized technicians. This innovation facilitates earlier diagnosis and targeted treatment for patients, particularly for non-convulsive seizures, thereby reducing the risk of complications and improving overall patient outcomes. Established in 2014 and based in Mountain View, California, Ceribell is committed to enhancing care in hospital ICUs, inpatient units, and emergency departments.

Boundless Bio

Series B in 2021
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

Invivyd

Series C in 2021
Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.

Entrada Therapeutics

Series B in 2021
Entrada Therapeutics, Inc. is a biotechnology company focused on treating diseases through the intracellular delivery of biologics, such as proteins, peptides, and nucleic acids. Founded in 2016 and based in Boston, Massachusetts, the company aims to transform patient care by developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible. Entrada's technology addresses challenges associated with delivering both large and small molecules, significantly enhancing the efficiency of therapeutic delivery into the cytosol. Its pipeline includes innovative therapies for neuromuscular diseases and other conditions, utilizing proprietary Endosomal Escape Vehicle (EEV) therapeutics to improve treatment outcomes across various organs and tissues.

OncoResponse

Series C in 2021
OncoResponse Inc. is a Houston-based immuno-oncology company focused on discovering innovative cancer therapies through its proprietary human antibody platform. The company specializes in identifying fully human monoclonal antibodies that target high-value immuno-oncology targets, particularly those associated with immunosuppressive myeloid biology. By exploring the adaptive immune responses of cancer patients who have successfully undergone checkpoint inhibition, OncoResponse aims to develop therapeutic antibodies that can mitigate tumor microenvironment immunosuppression and enhance immune activation. This approach seeks to transform cold tumors into hot tumors, thereby improving treatment outcomes for cancer patients.

Absci

Venture Round in 2021
Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

ElevateBio

Series C in 2021
ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, focused on the development of cell and gene-based therapies for treating cancer and viral infections. Founded in 2017 by Vikas Sinha, Mitchell Finer, and David Hallal, ElevateBio operates a portfolio of companies dedicated to creating life-changing medicines. The company collaborates with leading scientists and innovators to build this portfolio and has established a centralized facility that streamlines the transition from research and development to the commercialization of these therapies. This integrated approach enhances efficiency and accelerates the availability of medical products aimed at addressing severe diseases.

AgomAb Therapeutics

Series B in 2021
AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers. Founded in 2017 and based in Rehovot, Israel, the company aims to address genetically defined patient populations by targeting the tumorigenic drivers of cancer. Its lead product candidate, AL101, is an intravenous gamma secretase inhibitor currently undergoing Phase II clinical trials for the treatment of recurrent and metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala is developing AL102, an oral gamma secretase inhibitor, which is in Phase I clinical trials for desmoid tumors and has a collaboration with Novartis to further develop this compound for multiple myeloma. The company's innovative approach combines bioinformatics and next-generation sequencing to deliver targeted therapies to underserved patient populations.

Evox Therapeutics

Series C in 2021
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

Excision BioTherapeutics

Series A in 2021
Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

Verve Therapeutics

Series B in 2021
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Beam Therapeutics

Post in 2021
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients with serious diseases. Its therapeutic portfolio includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, and glycogen storage disorder 1A, as well as therapies for ocular and central nervous system disorders. Beam's base editing technology allows for targeted modifications at a single base in the genome without creating double-stranded breaks in DNA, positioning it as a pioneer in the field of genetic medicine. The company's pipeline includes several programs, such as BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201, reflecting its commitment to advancing genetic therapies.

Gritstone bio

Post in 2020
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

SomaLogic

Series A in 2020
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.

Neuron23

Series B in 2020
Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Neurogene

Series B in 2020
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.

RayzeBio

Series B in 2020
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

MedAvail

Series E in 2020
MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada. It integrates automated pharmacy services into clinics and other healthcare points through its proprietary technology. The company offers comprehensive services via its robotic dispensing platform, the MedAvail MedCenter, and includes home delivery operations. MedAvail primarily operates SpotRx, a telehealth-enabled retail pharmacy that provides remote pharmacist consultations through an on-site dispensing kiosk, catering mainly to Medicare patients in the United States. Additionally, the Pharmacy Technology segment focuses on developing and commercializing the MedCenter for direct sale or lease to third-party customers.

Achilles Therapeutics

Series C in 2020
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Mammoth Biosciences

Series C in 2020
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Impulse Dynamics

Venture Round in 2020
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Nuvation Bio

Post in 2020
Nuvation Bio Inc. is a biopharmaceutical company dedicated to developing innovative therapies for oncology, addressing unmet medical needs in the treatment of challenging cancers that have not responded to conventional therapies. Founded in 2018 and based in New York, with an additional office in San Francisco, the company has a portfolio of drug development candidates aimed at improving patient outcomes. One of its key clinical-stage candidates is NUV-868, an oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. Additionally, Nuvation Bio is advancing its proprietary small molecule Drug-Drug Conjugate platform, further expanding its therapeutic arsenal in oncology.

Absci

Series E in 2020
Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.

Augmedix

Private Equity Round in 2020
Augmedix, Inc. is a healthcare technology company based in San Francisco, California, with additional offices in Menlo Park and Dhaka, Bangladesh. Founded in 2012, Augmedix specializes in remote medical documentation and live clinical support through its cloud-based platform. The application transforms natural clinician-patient conversations into organized medical notes in real time, allowing healthcare providers to focus more on patient care and reducing the administrative burden associated with electronic health record documentation. By partnering with hospitals and health systems, Augmedix enhances clinical efficiency and decision-making, ultimately improving operational and financial outcomes. The platform is designed for use by both large healthcare organizations and individual practitioners, charging service fees for access to its remote documentation and clinical support services.

Lava Therapeutics

Series C in 2020
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Escient Pharmaceuticals

Series B in 2020
Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.

Science 37

Venture Round in 2020
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.

Annexon Biosciences

Series D in 2020
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Shattuck Labs

Series B in 2020
Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. The company utilizes its proprietary Agonist Redirected Checkpoint (ARC) platform, which involves dual-function fusion proteins designed to enhance immune responses against tumors. Its lead product candidate, SL-172154, is undergoing Phase 1 clinical trials for the treatment of ovarian cancer, while another candidate, SL-279252, is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials for advanced solid tumors and lymphoma. Shattuck Labs aims to address a variety of cancer types through its research in immuno-oncology, leveraging its technology to promote effective immune responses and improve patient outcomes. Founded in 2016, the company is committed to advancing the field of biologic medicine.

Atea Pharmaceuticals

Series D in 2020
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.

Clear Labs

Venture Round in 2020
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

CorVent

Seed Round in 2020
CorVent Medical specializes in the development, manufacturing, and marketing of ventilation and respiratory products aimed at addressing acute, sub-acute, and home care needs. The company has created the RESPOND ventilation platform, a compact and lightweight ventilator designed for quick deployment in various clinical settings and stockpiles. Weighing only 15 pounds, the RESPOND ventilator meets the ICU primary ventilation standard and is engineered for maintenance-free operation with a long shelf life, ensuring reliability and low total ownership costs. By utilizing advanced technologies, CorVent Medical provides healthcare providers with cost-effective solutions to manage respiratory insufficiency, allowing them to efficiently focus on critical patient care.

Lifesprout

Series A in 2020
LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

Genalyte

Series C in 2020
Genalyte, Inc. is a clinical and diagnostic life science company that specializes in rapid diagnostic testing solutions for healthcare providers and researchers. Founded in 2007 and based in San Diego, California, Genalyte has developed the Maverick platform, which utilizes silicon photonics technology to directly measure the binding of biomolecules, such as antibodies and proteins, to silicon photonic biosensors. This innovative approach allows for the quick detection of various health conditions, including autoimmune diseases, cancer biomarkers, and infectious agents. The company’s systems enable mobile laboratories to deliver real-time diagnostics in under thirty minutes, enhancing the quality of care while optimizing resource use within the healthcare system.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.